Supplementary Fig. S1: Study Design and Objectives

**Legend:**

**Solid arrows:** Objectives related to adolescent survivors (5 to 10 years post-diagnosis)

**Dashed arrows:** Objectives related to adult survivors (> 10 years post-diagnosis)

**Description:** This figure summarizes the study design and objectives of this study.

**Objective 1:** To evaluate the concurrent association between uric acid levels and pre-determined neurocognitive measures of attention, executive function and processing speed in adolescent survivors during the early survivorship phase

**Objective 1 (Ex):** Exploratory objective: To evaluate the temporal association between treatment exposures and uric acid levels in adolescent survivors

**Objective 2a:** To evaluate the concurrent association between uric acid levels and pre-determined neurocognitive measures of attention, executive function and processing speed in adult survivors during the late survivorship phase

**Objective 2b:** To evaluate the temporal association between uric acid levels during adolescence and neurocognitive measures of attention, executive function and processing speed in adult survivors during the late survivorship phase

**Objective 2c:** To evaluate the temporal association between uric acid levels during adolescence and pre-determined cardiovascular risk factors in adult survivors during the late survivorship phase

**Objective 2d**: To evaluate the concurrent association between pre-determined cardiovascular risk factors and neurocognitive function in adult survivors during the late survivorship phase

**Objective 2 (Ex):** Exploratory objective: To evaluate the temporal association between treatment exposures and uric acid levels during both early and late survivorship phases in adult survivors

